Long-term Investigation of Resveratrol in Obesity

Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01412645

Acronym

LIRMOI

Enrollment

Registered

2011-08-09

Start date

2011-08-31

Completion date

2013-08-31

Last updated

2013-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Insulin Sensitivity, Obesity, Osteoporosis

Keywords

Obesity, Inflammation, Metabolic Syndrome, Insulin sensitivity, Osteoporosis, Bone turnover, Ectopic fat accumulation, Resveratrol

Brief summary

The aim of this study is to investigate potential metabolic effects of resveratrol in men with metabolic syndrome(otherwise healthy). The investigators hypothesize that resveratrol has an anti-inflammatory effect, and will increase insulin sensitivity, change the fat- and sugar-metabolism, and down-regulate bone-turnover.

Detailed description

The study will be done in a collaboration between two PhD students, who focus on effects in adipose- and muscle- tissue, and bone tissue respectively. The investigators will look at changes in * inflammation-markers * biochemical markers of fat- and sugar-metabolism * gene-expression in fat- and muscle-tissue * body composition (DXA (whole body) and MR spectroscopy) * biochemical markers of bone-metabolism * Bone Mineral Density (DXA scans) * bone structure (QCT) * gene-expression and cytokines in bone marrow Some of the volunteers will have their insulin sensitivity measured.

Interventions

DIETARY_SUPPLEMENTResveratrol

500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or 1 placebo 2 times daily for 4 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * 30-60 years old * Metabolic Syndrome * Written informed consent

Exclusion criteria

* Diabetes, thyroid or parathyroid disease, hypogonadism * Treatment-requiring osteoporosis * Heart, liver or kidney disease * Present or previous malignancy * MR contraindication * Alcohol dependency * Weight \> 130 kilograms

Design outcomes

Primary

Measure	Time frame
Changes from Baseline in markers of inflammation (hs-CRP) in blood after 4 months of treatment with either resveratrol or placebo	4 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026